BR112023015191A2 - Agentes terapêuticos e de diagnóstico e usos dos mesmos - Google Patents
Agentes terapêuticos e de diagnóstico e usos dos mesmosInfo
- Publication number
- BR112023015191A2 BR112023015191A2 BR112023015191A BR112023015191A BR112023015191A2 BR 112023015191 A2 BR112023015191 A2 BR 112023015191A2 BR 112023015191 A BR112023015191 A BR 112023015191A BR 112023015191 A BR112023015191 A BR 112023015191A BR 112023015191 A2 BR112023015191 A2 BR 112023015191A2
- Authority
- BR
- Brazil
- Prior art keywords
- binding
- cells
- car
- binding molecules
- hcmv
- Prior art date
Links
- 239000000032 diagnostic agent Substances 0.000 title abstract 2
- 229940039227 diagnostic agent Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 230000027455 binding Effects 0.000 abstract 9
- 241000701024 Human betaherpesvirus 5 Species 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101150044134 US28 gene Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 230000009871 nonspecific binding Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000009870 specific binding Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/089—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/04—Varicella-zoster virus
- C07K14/045—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/088—Varicella-zoster virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
Abstract
agentes terapêuticos e de diagnóstico e usos dos mesmos. a presente invenção fornece moléculas de ligação tendo uma ou mais de (de preferência todas) ligação altamente específica à proteína us28 do citomegalovírus humano (hcmv), níveis muito baixos de ligação não específica a células saudáveis (não infectadas) e/ou uma capacidade de ligação agnóstica de cepa, bem como moléculas de ácido nucleico que codificam as ditas moléculas de ligação. as moléculas de ligação são projetadas para se ligarem ao domínio extracelular 3 (ecd3) de uma proteína us28 do citomegalovírus humano (hcmv), o terceiro dos quatro domínios extracelulares apresentados por us28, correspondendo às posições 167 a 183 da sequência da proteína us28, conforme definido pela seq id no:5. as moléculas de ligação da presente invenção demonstraram ter excelentes propriedades de ligação, incluindo especificidade de ligação particular para cânceres infectados por hcmv agressivos e/ou metastáticos, incluindo cânceres de mama. em certas modalidades preferidas, a molécula de ligação é selecionada a partir de um anticorpo (incluindo, por exemplo, um anticorpo bite) e um receptor de antígeno quimérico (car), ou variantes funcionais, fragmentos, proteínas de fusão e/ou conjugados dos mesmos. também são fornecidas células que expressam as ditas moléculas de ligação, como células que expressam car, incluindo células car-t, células car-nk e células car-m.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB2101228.1A GB2603166A (en) | 2021-01-29 | 2021-01-29 | Therapeutic and Diagnostic Agents and Uses Thereof |
PCT/EP2022/052130 WO2022162192A2 (en) | 2021-01-29 | 2022-01-28 | Therapeutic and diagnostic agents and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023015191A2 true BR112023015191A2 (pt) | 2023-12-12 |
Family
ID=74865391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023015191A BR112023015191A2 (pt) | 2021-01-29 | 2022-01-28 | Agentes terapêuticos e de diagnóstico e usos dos mesmos |
Country Status (15)
Country | Link |
---|---|
US (1) | US20240199724A1 (pt) |
EP (1) | EP4232057A2 (pt) |
JP (1) | JP2024506550A (pt) |
KR (1) | KR20230150813A (pt) |
CN (1) | CN116847864A (pt) |
AU (1) | AU2022213494A1 (pt) |
BR (1) | BR112023015191A2 (pt) |
CA (1) | CA3205854A1 (pt) |
CL (1) | CL2023002234A1 (pt) |
CO (1) | CO2023010063A2 (pt) |
GB (1) | GB2603166A (pt) |
IL (1) | IL304734A (pt) |
MX (1) | MX2023008886A (pt) |
TW (1) | TW202246304A (pt) |
WO (1) | WO2022162192A2 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3090321A1 (en) * | 2018-02-05 | 2019-08-08 | Stichting Vu | Inverse agonistic anti-us28 antibodies |
US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
GB202201137D0 (en) * | 2022-01-28 | 2022-03-16 | Thelper As | Therapeutic and diagnostic agents and uses thereof |
CN115947869B (zh) * | 2022-11-28 | 2023-12-12 | 广州佰芮慷生物科技有限公司 | 一种靶向人巨细胞病毒的嵌合抗原受体、car-nk细胞及用途 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5874A (en) | 1848-10-24 | Apparatus eob baking- water | ||
US541A (en) | 1837-12-26 | Daniel desmond | ||
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
JPH049249A (ja) | 1990-04-27 | 1992-01-14 | Kusuda:Kk | 塗型剤吹き付け機 |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
DK0656946T4 (da) | 1992-08-21 | 2010-07-26 | Univ Bruxelles | Immunoglobuliner uden lette kæder |
US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
US5716081A (en) | 1996-03-11 | 1998-02-10 | Automotive Products (Usa), Inc. | Spring clip for quick connect coupling |
US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
ES2294799T3 (es) | 1996-06-27 | 2008-04-01 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana. |
GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
JP2003516124A (ja) | 1999-10-15 | 2003-05-13 | ユニバーシティー オブ マサチューセッツ | 標的とした遺伝的干渉の手段としてのrna干渉経路遺伝子 |
US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
CA2420944A1 (en) * | 2000-08-30 | 2002-03-07 | Chemocentryx, Inc. | Inhibition of cmv infection and dissemination |
US8425898B2 (en) * | 2008-06-20 | 2013-04-23 | Duke University | Compositions, methods, and kits for eliciting an immune response |
MX354359B (es) | 2011-03-29 | 2018-02-28 | Roche Glycart Ag | Variantes de fragmento cristalizable (fc) de los anticuerpos. |
CA3090321A1 (en) * | 2018-02-05 | 2019-08-08 | Stichting Vu | Inverse agonistic anti-us28 antibodies |
CN114206944A (zh) * | 2019-07-12 | 2022-03-18 | 哥本哈根大学 | 用于治疗cmv感染相关疾病的融合毒素蛋白 |
EP4010079A1 (en) * | 2019-08-05 | 2022-06-15 | Stichting VU | Identification and elimination of hcmv-infected cells |
GB2595299B (en) | 2020-05-21 | 2022-08-03 | Mabsolve Ltd | Modified immunoglobulin FC regions |
-
2021
- 2021-01-29 GB GB2101228.1A patent/GB2603166A/en active Pending
-
2022
- 2022-01-28 AU AU2022213494A patent/AU2022213494A1/en active Pending
- 2022-01-28 MX MX2023008886A patent/MX2023008886A/es unknown
- 2022-01-28 CN CN202280012134.8A patent/CN116847864A/zh active Pending
- 2022-01-28 BR BR112023015191A patent/BR112023015191A2/pt unknown
- 2022-01-28 US US18/272,255 patent/US20240199724A1/en active Pending
- 2022-01-28 CA CA3205854A patent/CA3205854A1/en active Pending
- 2022-01-28 WO PCT/EP2022/052130 patent/WO2022162192A2/en active Application Filing
- 2022-01-28 EP EP22702714.1A patent/EP4232057A2/en active Pending
- 2022-01-28 KR KR1020237029200A patent/KR20230150813A/ko unknown
- 2022-01-28 TW TW111104017A patent/TW202246304A/zh unknown
- 2022-01-28 JP JP2023546197A patent/JP2024506550A/ja active Pending
-
2023
- 2023-07-25 IL IL304734A patent/IL304734A/en unknown
- 2023-07-27 CL CL2023002234A patent/CL2023002234A1/es unknown
- 2023-07-28 CO CONC2023/0010063A patent/CO2023010063A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3205854A1 (en) | 2022-08-04 |
US20240199724A1 (en) | 2024-06-20 |
MX2023008886A (es) | 2023-10-16 |
WO2022162192A2 (en) | 2022-08-04 |
GB2603166A (en) | 2022-08-03 |
CO2023010063A2 (es) | 2023-10-30 |
AU2022213494A1 (en) | 2023-07-27 |
JP2024506550A (ja) | 2024-02-14 |
IL304734A (en) | 2023-09-01 |
TW202246304A (zh) | 2022-12-01 |
GB202101228D0 (en) | 2021-03-17 |
KR20230150813A (ko) | 2023-10-31 |
WO2022162192A3 (en) | 2022-09-15 |
CN116847864A (zh) | 2023-10-03 |
CL2023002234A1 (es) | 2024-02-23 |
EP4232057A2 (en) | 2023-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112023015191A2 (pt) | Agentes terapêuticos e de diagnóstico e usos dos mesmos | |
Hirakata et al. | Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease | |
Akiyama et al. | Hyaluronate receptors mediating glioma cell migration and proliferation | |
Ashcom et al. | The human alpha 2-macroglobulin receptor: identification of a 420-kD cell surface glycoprotein specific for the activated conformation of alpha 2-macroglobulin. | |
Chicoine et al. | Vascular delivery of rAAVrh74. MCK. GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin α2 surrogates | |
Chiefari et al. | Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: a role in NIS expression regulation? | |
BRPI0618399A2 (pt) | região de ligação de antìgeno isolada que é especìfica para cd38, anticorpo isolado ou um fragmento funcional do mesmo que é especìfico para cd38, anticorpo isolado ou um fragmento funcional do mesmo, imunoglobulina isolada, cadeia pesada variável de uma região de ligação de antìgeno isolada, cadeia leve variável de uma região de ligação de antìgeno isolada, seqüência isolada de ácido nucléico, seqüência de ácido nucléico que codifica uma cadeia pesada variável de uma região de ligação de antìgeno isolada, seqüência de ácido nucléico, vetor, célula isolada, composição farmacêutica, uso da composição farmacêutica, método de indução de mortandade especìfica das células de tumor que expressam cd38, método de detecção da mortandade especìfica das células de tumor que expressam cd38, método de detecção da presença de cd38 em um tecido ou em célula de origem de miniporco, método de detecção de cd38 em um eritrócito que expressa cd38 e composição de diagnóstico | |
Tsiantoulas et al. | APRIL limits atherosclerosis by binding to heparan sulfate proteoglycans | |
Mor‐Vaknin et al. | DEK in the synovium of patients with juvenile idiopathic arthritis: characterization of DEK antibodies and posttranslational modification of the DEK autoantigen | |
BRPI0417429A (pt) | anticorpo monoclonal isolado ou uma porção de ligação de antìgeno deste, composição, imunoconjugado, molécula biespecìfica, vetor de expressão, célula hospedeira, camundongo transgênico, hibridoma, e, métodos de inibir uma resposta inflamatória ou autoimune, de tratar uma doença inflamatória ou autoimune, de tratar uma infecção viral ou bacteriana e de preparar um anticorpo anti-ip-10 | |
Kazemi et al. | VEGF121 and VEGF165 differentially promote vessel maturation and tumor growth in mice and humans | |
ES2235329T3 (es) | Procedimiento basado en el uso de bacteriofagos para la deteccion de moleculas biologicas en muestras biologicas. | |
CY1118462T1 (el) | Μονοκλωνικο αντισωμα κατα της πρωτεϊνης συνδεσης οστεοπροτεγερινης | |
BR112012013915A2 (pt) | anticorpos anti-c4. 4a e usos dos mesmos | |
Katarzyna et al. | Collagen Q–a potential target for autoantibodies in myasthenia gravis | |
BRPI0418766A (pt) | anticorpos e moléculas derivadas destes que se ligam às proteìnas steap-1 | |
Khayati et al. | EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by VEGF | |
Cohen et al. | Purified autoantibodies against glucose-regulated protein 78 (GRP78) promote apoptosis and decrease invasiveness of ovarian cancer cells | |
Laman et al. | Muramyl peptides activate innate immunity conjointly via YB1 and NOD2 | |
Fernandes-Cerqueira et al. | Targeting of anti-citrullinated protein/peptide antibodies in rheumatoid arthritis using peptides mimicking endogenously citrullinated fibrinogen antigens | |
BRPI0808940A8 (pt) | anticorpo humano ou fragmento de ligação do mesmo, antígeno, polinucleotídeo, vetor, célula hospedeira, método para preparar um anticorpo ou um fragmento de ligação ou cadeia(s) de imunoglobulina do mesmo, anticorpo, cadeia de imunoglobulina ou um fragmento de ligação do mesmo, composição, usos do anticorpo ou fragmento de ligação, de um antígeno, de um polinucleotídeo, de um vetor, ou de uma célula, e de uma molécula de ligação a antígeno tumoral, método para clonagem molecular de um anticorpo, e, kit para o diagnóstico de um tumor | |
KR20200035194A (ko) | 재조합 인간 cd38-세포외 도메인을 포함하는 조성물, 방법 및/또는 키트 | |
Wilson et al. | Expression of a long variant of CRACR2A that belongs to the Rab GTPase protein family in endothelial cells | |
Dumortier et al. | B and T cell responses to the spliceosomal heterogeneous nuclear ribonucleoproteins A2 and B1 in normal and lupus mice | |
BR0116763A (pt) | Anticorpos humanos especìficos para terapia seletiva do c ncer |